1. Home
  2. SLBT vs MPLT Comparison

SLBT vs MPLT Comparison

Compare SLBT & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SL Science Holding Limited Ordinary Shares

SLBT

SL Science Holding Limited Ordinary Shares

N/A

Current Price

$2.69

Market Cap

1.5B

Sector

N/A

ML Signal

N/A

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$11.15

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLBT
MPLT
Founded
N/A
2018
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2025
2025

Fundamental Metrics

Financial Performance
Metric
SLBT
MPLT
Price
$2.69
$11.15
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$32.67
AVG Volume (30 Days)
72.2K
1.3M
Earning Date
N/A
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.39
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.54
$9.10
52 Week High
$6.25
$40.43

Technical Indicators

Market Signals
Indicator
SLBT
MPLT
Relative Strength Index (RSI) 40.10 29.77
Support Level $2.54 $10.83
Resistance Level $3.40 $20.20
Average True Range (ATR) 0.17 0.94
MACD 0.05 0.52
Stochastic Oscillator 0.00 12.20

Price Performance

Historical Comparison
SLBT
MPLT

About SLBT SL Science Holding Limited Ordinary Shares

SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: